A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID:
MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [betanin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]]; [CTNNA1 protein affects the susceptibility to Cisplatin] which results in decreased expression of BCL2 protein; [epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; betanin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; chelerythrine inhibits the reaction [sodium arsenite inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]]; Cisplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein; Eicosanoids analog inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; fisetin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; formononetin promotes the reaction [Cisplatin results in increased expression of BCL2 protein]; FSCN2 protein inhibits the reaction [[CTNNA1 protein affects the susceptibility to Cisplatin] which results in decreased expression of BCL2 protein]; Grape Seed Proanthocyanidins inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Roflumilast inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; Roflumilast inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Cisplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein]; sodium arsenite inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Tadalafil inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; U 0126 inhibits the reaction [Cisplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein]; uranyl acetate inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Venlafaxine Hydrochloride inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]]
Cisplatin results in decreased expression of BCL2; Cisplatin results in decreased expression of BCL2 mRNA; Cisplatin results in decreased expression of BCL2 protein
[Cisplatin co-treated with TNF protein] results in decreased expression of BCL2 mRNA; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; [SLC39A8 protein results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2 protein; ABCB1 protein inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]]; anemoside B4 inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; apelin-13 peptide inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Aspirin inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; Aspirin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; hesperetin promotes the reaction [Cisplatin results in increased expression of BCL2 protein]; IL6 gene mutant form promotes the reaction [Cisplatin results in increased expression of BCL2 mRNA]; Inositol inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Lithium Chloride inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Luteolin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; PARK7 protein affects the reaction [Cisplatin results in decreased expression of BCL2 protein]; Rosmarinic Acid inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; sarpogrelate inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Streptozocin inhibits the reaction [Cisplatin results in increased expression of BCL2 protein]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; [[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 protein; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 mRNA; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein; [andrographolide co-treated with Cisplatin] results in decreased expression of BCL2 mRNA; [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with Vorinostat] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Quercetin] results in decreased expression of BCL2 protein; [Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 protein; [Cisplatin results in increased expression of MIR630] which results in decreased expression of BCL2 mRNA; [CXCL8 results in increased expression of BCL2 mRNA] which results in decreased susceptibility to Cisplatin; [CXCL8 results in increased expression of BCL2 protein] which results in decreased susceptibility to Cisplatin; [Estradiol results in increased expression of BCL2 mRNA] which results in increased susceptibility to Cisplatin; [MIR205 mRNA results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2 protein; [MIR342 mRNA results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2 protein; [MIR497 results in decreased expression of BCL2 protein] which results in increased susceptibility to Cisplatin; [Paclitaxel results in increased phosphorylation of BCL2 protein] which results in increased susceptibility to Cisplatin; [Proadifen co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Quercetin results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2 protein; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; [SLC39A8 protein affects the susceptibility to Cisplatin] which affects the expression of BCL2 protein; [Theophylline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [TNFSF10 protein co-treated with Cisplatin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [tubeimoside I co-treated with Cisplatin] results in decreased expression of BCL2 protein; [YAP1 protein promotes the reaction [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]] which results in decreased expression of BCL2 protein; ABCB1 protein inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; astilbin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; BCL2 inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; BCL2 inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; BCL2 inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; BCL2 protein inhibits the reaction [[Cisplatin co-treated with FASLG protein] results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [[Cisplatin co-treated with FASLG protein] results in increased activity of CASP8 protein]; BCL2 protein inhibits the reaction [[Cisplatin co-treated with FASLG protein] results in increased activity of CASP9 protein]; BCL2 protein inhibits the reaction [Cisplatin affects the localization of BAX protein]; BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; chrysin inhibits the reaction [Cisplatin results in increased expression of BCL2 protein]; Cisplatin promotes the reaction [jinfukang results in decreased expression of BCL2 mRNA]; Cisplatin promotes the reaction [Metformin results in decreased expression of BCL2 protein]; Cisplatin promotes the reaction [Oleanolic Acid results in decreased expression of BCL2 protein]; Cisplatin promotes the reaction [Roflumilast results in decreased expression of BCL2 mRNA]; Cisplatin promotes the reaction [Roflumilast results in decreased expression of BCL2 protein]; Cisplatin promotes the reaction [SC-66 compound results in decreased expression of BCL2 protein]; Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; GJA1 protein affects the reaction [Cisplatin results in decreased expression of BCL2 protein]; hesperetin promotes the reaction [Cisplatin results in increased expression of BCL2 protein]; ING4 protein promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; Inositol inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; jinfukang promotes the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; madecassoside inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Cisplatin affects the expression of BCL2 protein]; Noscapine promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; Oleanolic Acid promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; Omeprazole inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; RASAL2 protein inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Roflumilast promotes the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; Roflumilast promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; sarpogrelate inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; SC-66 compound promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; SRT1720 inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; tetraarsenic tetrasulfide promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; Y 27632 inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]
